Evidence map›Paper›PMID 34022936›Full record

ArticleBreast cancer research : BCR2021

Accelerated aging in normal breast tissue of women with breast cancer.

Shoghag Panjarian, Jozef Madzo, Kelsey Keith, Carolyn M Slater, Carmen Sapienza, Jaroslav Jelinek, Jean-Pierre J Issa

Open access · goldAbstract read
In one paragraph

Article in Breast cancer research : BCR, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Selective Estrogen Receptor Modulators' (SERMs) Influence onInternational journal of molecular sciences · 2024
    Article
  7. Natural Compounds for Preventing Age-Related Diseases and Cancers.International journal of molecular sciences · 2024
    Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Shoghag PanjarianCoriell Institute for Medical Research, 403 Haddon Ave., Camden, NJ, 08103, USA. spanjarian@coriell.org.ORCID 0000-0003-0861-9767
Jozef MadzoCoriell Institute for Medical Research, 403 Haddon Ave., Camden, NJ, 08103, USA.
Kelsey KeithCoriell Institute for Medical Research, 403 Haddon Ave., Camden, NJ, 08103, USA.
Carolyn M SlaterFox Chase Cancer Center, Philadelphia, PA, USA.
Carmen SapienzaFels Institute for Cancer Research, Temple University School of Medicine, Philadelphia, PA, USA.
Jaroslav JelinekCoriell Institute for Medical Research, 403 Haddon Ave., Camden, NJ, 08103, USA.
Jean-Pierre J IssaCoriell Institute for Medical Research, 403 Haddon Ave., Camden, NJ, 08103, USA.
Coriell Institute For Medical Research · USFox Chase Cancer Center · USTemple University · US

Funding

Susan G. Komen PDF17479825W.W.Smith Charitable Trust C1908
6 · The paper itself

Abstract

backgroundDNA methylation alterations have similar patterns in normal aging tissue and in cancer. In this study, we investigated breast tissue-specific age-related DNA methylation alterations and used those methylation sites to identify individuals with outlier phenotypes. Outlier phenotype is identified by unsupervised anomaly detection algorithms and is defined by individuals who have normal tissue age-dependent DNA methylation levels that vary dramatically from the population mean.

methodsWe generated whole-genome DNA methylation profiles (GSE160233) on purified epithelial cells and used publicly available Infinium HumanMethylation 450K array datasets (TCGA, GSE88883, GSE69914, GSE101961, and GSE74214) for discovery and validation.

resultsWe found that hypermethylation in normal breast tissue is the best predictor of hypermethylation in cancer. Using unsupervised anomaly detection approaches, we found that about 10% of the individuals (39/427) were outliers for DNA methylation from 6 DNA methylation datasets. We also found that there were significantly more outlier samples in normal-adjacent to cancer (24/139, 17.3%) than in normal samples (15/228, 5.2%). Additionally, we found significant differences between the predicted ages based on DNA methylation and the chronological ages among outliers and not-outliers. Additionally, we found that accelerated outliers (older predicted age) were more frequent in normal-adjacent to cancer (14/17, 82%) compared to normal samples from individuals without cancer (3/17, 18%). Furthermore, in matched samples, we found that the epigenome of the outliers in the pre-malignant tissue was as severely altered as in cancer.

conclusionsA subset of patients with breast cancer has severely altered epigenomes which are characterized by accelerated aging in their normal-appearing tissue. In the future, these DNA methylation sites should be studied further such as in cell-free DNA to determine their potential use as biomarkers for early detection of malignant transformation and preventive intervention in breast cancer.

Indexed as

AgingBreastBreast NeoplasmsCpG IslandsDNA MethylationEpigenomeFemaleHumansPhenotypeAccelerated agingDNA methylationOutliersPredicted age

Identifiers

PMID34022936
PMCPMC8140515
OpenAlexW3165787714

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.